Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®)

Policy Number: 2021D0055K
Effective Date: May 1, 2021

Table of Contents

Coverage Rationale ................................................................. 1
Applicable Codes .................................................................... 7
Background ............................................................................. 8
Benefit Considerations ......................................................... 8
Clinical Evidence .................................................................... 9
U.S. Food and Drug Administration ....................................... 11
Centers for Medicare and Medicaid Services ........................ 12
References ............................................................................. 12
Policy History/Revision Information ....................................... 13
Instructions for Use ................................................................. 14

Related Commercial Policy
• Provider Administered Drugs – Site of Care

Community Plan Policy
• Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®)

Coverage Rationale

This policy provides information about the use of certain specialty pharmacy medications administered by either the subcutaneous (SC) or intravenous (IV) route.

This policy refers to the following drug products:
● Cinqair® (reslizumab)
● Fasenra® (benralizumab)
● Nucala® (mepolizumab)

Proven

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Nucala for provider administration, is proven for the treatment of EGPA.¹

Nucala for provider administration, is medically necessary for the treatment of EGPA when all of the following criteria are met:
● Initial Therapy
  o Diagnosis of relapsing or refractory EGPA as defined by all of the following:¹³
    ▪ Diagnosis of EGPA; and
    ▪ Past medical history or presence of asthma; and
    ▪ Presence of at least two of the following characteristics typical of EGPA:
      – Histopathological evidence of:
        ● Eosinophilic vasculitis
        ● Perivascular eosinophilic infiltration
        ● Eosinophil-rich granulomatous inflammation
      – Neuropathy, mono or poly (motor deficit or nerve conduction abnormality)
      – Pulmonary infiltrates, non-fixed
      – Sino-nasal abnormality
- Cardiomyopathy (established by echocardiography or MRI)
- Glomerulonephritis (hematuria, red cell casts, proteinuria)
- Alveolar hemorrhage
- Palpable purpura
- Anti-neutrophil cytoplasmic antibody (ANCA) positive

and

- History of relapsing or refractory disease defined as one of the following:
  - Relapsing disease as defined as a past history (within the past 2 years) of at least one EGPA relapse (requiring additional or dose escalation of corticosteroids or immunosuppressant, or hospitalization); or
  - Refractory disease as defined as failure to attain remission within the prior 6 months following induction treatment with standard therapy regimens

and

- Patient is currently taking standard therapy (corticosteroids with or without immunosuppressive therapy); and
- Documentation required to support one of the following:
  - Physician attestation that the patient or caregiver are not competent or are physically unable to administer the Nucala product FDA labeled for self-administration; or
  - Patient has experienced severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, or hypotension) to Nucala within the past 6 months and requires administration and direct monitoring by a healthcare professional; or
  - Patient is new to therapy with Nucala and requires initial dose to be directly monitored by a healthcare professional before continued self-administration (Note: authorization will be for 1 dose)

and

- Patient is not receiving Nucala in combination with any of the following:
  - Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
  - Anti-IgE therapy [e.g., Xolair (omalizumab)]
  - Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]

and

- Nucala dosing for EGPA is in accordance with the U. S. Food and Drug Administration approved labeling: 300mg subcutaneously once every 4 weeks; and
- Prescribed by or in consultation with a pulmonologist, rheumatologist, or allergist/immunologist; and
- Initial authorization will be for no more than 6 months.

Reauthorization/Continuation of Care Criteria

Nucala, for provider administration, for the treatment of EGPA, authorization for continued use will be approved based on all of the following criteria:

- Documentation of positive clinical response as demonstrated by at least one of the following:
  - Reduction in the frequency and/or severity of relapses
  - Reduction or discontinuation of doses of corticosteroids and/or immunosuppressant
  - Disease remission
  - Reduction in severity or frequency of EGPA-related symptoms

and

- Documentation required to support one of the following:
  - Physician attestation that the patient or caregiver are not competent or are physically unable to administer the Nucala product FDA labeled for self-administration; or
  - Patient has experienced severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, or hypotension) to Nucala within the past 6 months and requires administration and direct monitoring by a healthcare professional

and

- Patient is not receiving Nucala in combination with any of the following:
  - Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
  - Anti-IgE therapy [e.g., Xolair (omalizumab)]
  - Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]

and

- Nucala dosing for EGPA is in accordance with the U. S. Food and Drug Administration approved labeling: 300mg subcutaneously once every 4 weeks; and
Severe Asthma

Cinqair
- Cinqair for intravenous use is proven for add-on therapy for patients who meet both of the following criteria:\(^2\)
  - Have an eosinophilic phenotype; and
  - Will be used as add-on maintenance therapy in the treatment of severe asthma.
- Cinqair is medically necessary when all of the following criteria are met: \(^2\)\(^6\)
  - Diagnosis of severe asthma; and
  - Classification of asthma as uncontrolled or inadequately controlled as defined by at least one of the following:
    - Poor symptom control (e.g., ACQ score consistently greater than 1.5 or ACT score consistently less than 20); or
    - Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months; or
    - Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician’s office visit for nebulizer or other urgent treatment); or
    - Airflow limitation (e.g., after appropriate bronchodilator withhold FEV1 less than 80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal)); or
    - Patient is currently dependent on maintenance therapy with oral corticosteroids for the treatment of asthma and
  - One of the following:
    - Asthma is an eosinophilic phenotype as defined by a baseline (pre-reslizumab) peripheral blood eosinophil level of ≥ 400 cells/μL within the past 4 weeks; or
    - Patient is currently dependent on maintenance therapy with oral corticosteroids for the treatment of asthma and
  - Used in combination with one of the following:
    - One maximally-dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta\(_2\) agonist (LABA) product [e.g., Advair/AirDuo Respliclick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]; or
    - Combination therapy including both of the following:
      - One high-dose (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco\(^\ast\)), mometasone furoate (Asmanex\(^\ast\)), beclomethasone dипropionate (QVAR\(^\ast\))]; and
      - One additional asthma controller medication [e.g., LABA - olodaterol (Striverdi\(^\ast\)) or indacaterol (Arca\(p\)ta\(^\ast\)), leukotriene receptor antagonist – montelukast (Singulair\(^\ast\)), theophylline]
  - One of the following (for Medicare reviews, refer to the CMS section*):
    - History of failure to a 4 month trial of Fasenra or Nucala; or
    - Contraindication or intolerance to Fasenra or Nucala and
  - Patient is not receiving Cinqair in combination with any of the following:
    - Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Fasenra (benralizumab)]
    - Anti-IgE therapy [e.g., Xolair (omalizumab)]
    - Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
  - Cinqair dosing for severe eosinophilic asthma is in accordance with the United States Food and Drug Administration approved labeling: 3 mg/kg intravenously once every 4 weeks; and
  - Prescribed by or in consultation with a pulmonologist or allergist/immunologist; and
  - Initial authorization will be for no more than 6 months.

Fasenra
- Fasenra for provider administration, is proven for add-on therapy for patients who meet both of the following criteria:
  - Has an eosinophilic phenotype; and
  - Will be used as add-on maintenance therapy in the treatment of severe asthma.
- Fasenra for provider administration, is medically necessary when all of the following criteria are met: \(^3\)\(^5\)\(^6\)\(^10\)\(^12\)
  - Diagnosis of severe asthma; and
o Classification of asthma as uncontrolled or inadequately controlled as defined by at least one of the following:
  ▪ Poor symptom control (e.g., Asthma Control Questionnaire [ACQ] score consistently greater than 1.5 or Asthma Control Test [ACT] score consistently less than 20); or
  ▪ Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months; or
  ▪ Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician’s office visit for nebulizer or other urgent treatment); or
  ▪ Airflow limitation (e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second (FEV1) less than 80% predicted [in the face of reduced FEV1/forced vital capacity (FVC) defined as less than the lower limit of normal]; or
  ▪ Patient is currently dependent on maintenance therapy with oral corticosteroids for the treatment of asthma and

  o One of the following:
    ▪ Asthma is an eosinophilic phenotype as defined by a baseline (pre-benralizumab) peripheral blood eosinophil level of ≥ 150 cells/μL within the past 6 weeks; or
    ▪ Patient is currently dependent on maintenance therapy with oral corticosteroids for the treatment of asthma and

  o Used in combination with one of the following:
    ▪ One maximally-dosed (appropriately adjusted for age) combination ICS/ LABA product [e.g., Advair/AirDuo Respliclick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]; or
    ▪ Combination therapy including both of the following:
      – One high-dose (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco’), mometasone furoate (Asmanex’), beclomethasone dipropionate (QVAR’)]; and
      – One additional asthma controller medication [e.g., LABA - olodaterol (Striverdi’) or indacaterol (Arcapta’); leukotriene receptor antagonist – montelukast (Singulair’); theophylline] and

  o Documentation required to support one of the following:
    ▪ Physician attestation that the patient or caregiver are not competent or are physically unable to administer the Fasenra product FDA labeled for self-administration; or
    ▪ Patient has experienced severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, or hypotension) to Fasenra within the past 6 months and requires administration and direct monitoring by a healthcare professional; or
    ▪ Patient is new to therapy with Fasenra and requires initial dose to be directly monitored by a healthcare professional before continued self-administration (Note: authorization will be for 1 dose) and

  o Patient is not receiving Fasenra in combination with any of the following:
    ▪ Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinquaïr (reslizumab)]
    ▪ Anti-IgE therapy [e.g., Xolair (omalizumab)]
    ▪ Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)] and
  
  o Fasenra dosing for severe eosinophilic asthma is in accordance with the United States Food and Drug Administration approved labeling: 30mg subcutaneously once every 4 weeks for 3 doses, then once every 8 weeks thereafter; and
  
  o Prescribed by or in consultation with a pulmonologist or allergist/immunologist; and
  
  o Initial authorization will be for no more than 6 months.

Nucala

● Nucala for provider administration is proven for add-on therapy for patients who meet both of the following criteria:¹
  o Has an eosinophilic phenotype; and
  o Will be used as add-on maintenance therapy in the treatment of severe asthma.

● Nucala for provider administration is medically necessary when all of the following criteria are met:¹,³,⁶
  o Diagnosis of severe asthma; and
  o Classification of asthma as uncontrolled or inadequately controlled as defined by at least one of the following:
    ▪ Poor symptom control (e.g., Asthma Control Questionnaire [ACQ] score consistently greater than 1.5 or Asthma Control Test [ACT] score consistently less than 20); or
    ▪ Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months; or

Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®)
UnitedHealthcare Commercial Medical Benefit Drug Policy

Proprietary Information of UnitedHealthcare. Copyright 2021 United HealthCare Services, Inc.
Respiratory Interleukins (Cinqair®️, Fasenra®️, & Nucala®️)

- Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician’s office visit for nebulizer or other urgent treatment); or
- Airflow limitation (e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second (FEV1) less than 80% predicted [in the face of reduced FEV1/forced vital capacity (FVC) defined as less than the lower limit of normal]; or
- Patient is currently dependent on maintenance therapy with oral corticosteroids for the treatment of asthma and
  - One of the following:
    - Asthma is an eosinophilic phenotype as defined by a baseline (pre-mepolizumab) peripheral blood eosinophil level of ≥ 150 cells/µL within the past 6 weeks; or
    - Patient is currently dependent on maintenance therapy with oral corticosteroids for the treatment of asthma and
  - Used in combination with one of the following:
    - One maximally-dosed (appropriately adjusted for age) combination ICS/ LABA product [e.g., Advair/AirDuo Respliclick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]; or
    - Combination therapy including both of the following:
      - One high-dose (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco®️), mometasone furoate (Asmanex®️), beclomethasone dipropionate (QVAR®️)]; and
      - One additional asthma controller medication [e.g., LABA - olodaterol (Striverdi®️) or indacaterol (Aracpta®️); leukotriene receptor antagonist – montelukast (Singular®️); theophylline]
    and
  - Documentation required to support one of the following:
    - Physician attestation that the patient or caregiver are not competent or are physically unable to administer the Nucala product FDA labeled for self-administration; or
    - Patient has experienced severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, or hypotension) to Nucala within the past 6 months and requires administration and direct monitoring by a healthcare professional; or
    - Patient is new to therapy with Nucala and requires initial dose to be directly monitored by a healthcare professional before continued self-administration (Note: authorization will be for 1 dose); or
    - Patient is ≤11 years of age
  and
  - Patient is not receiving Nucala in combination with any of the following:
    - Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
    - Anti-IgE therapy [e.g., Xolair (omalizumab)]
    - Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
  and
  - Nucala dosing for severe eosinophilic asthma is in accordance with the United States Food and Drug Administration approved labeling: 100mg subcutaneously once every 4 weeks; and
  - Prescribed by or in consultation with a pulmonologist or allergist/immunologist; and
  - Initial authorization will be for no more than 6 months.

Reauthorization/Continuation of Care Criteria

- For patients currently on Cinqair, Fasenra, or Nucala for the treatment of severe eosinophilic asthma, authorization for continued use will be approved based on all of the following criteria:
  - Documentation of positive clinical response as demonstrated by at least one of the following:
    - Reduction in the frequency of exacerbations
    - Decreased utilization of rescue medications
    - Increase in percent predicted FEV1 from pretreatment baseline
    - Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)
  and
  - Used in combination with an ICS-containing controller medication; and
  - Patient is not receiving the product in combination with any of the following:
 Another anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab), Nucala (mepolizumab)], respectively.
 Anti-IgE therapy [e.g., Xolair (omalizumab)]
 Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]

and

o One of the following:

 Nucala dosing for severe eosinophilic asthma is in accordance with the United States Food and Drug Administration approved labeling: 100mg subcutaneously once every 4 weeks; or
 Cinqair dosing for severe eosinophilic asthma is in accordance with the United States Food and Drug Administration approved labeling: 3 mg/kg intravenously once every 4 weeks; or
 Fasenra dosing for severe eosinophilic asthma is in accordance with the United States Food and Drug Administration approved labeling: 30 mg subcutaneously once every 8 weeks

and

o Prescribed by or in consultation with a pulmonologist or allergist/immunologist; and
o Reauthorization will be for no more than 12 months

For Fasenra and Nucala reauthorization/continuation only, documentation required to support one of the following:

o Physician attestation that the patient or caregiver are not competent or are physically unable to administer the Fasenra or Nucala product FDA labeled for self-administration; or

or

For Cinqair reauthorization/continuation only (for Medicare reviews, refer to the CMS section*), one of the following:

o History of failure to a 4 month trial of Fasenra or Nucala; or

or

Contraindication or intolerance to Fasenra or Nucala.

**Hypereosinophilic Syndrome (HES)**

**Nucala**

- Nucala for provider administration is proven for patients who meet the following criteria:
  - Diagnosis of HES for ≥6 months; and
  - There is no identifiable non-hematologic secondary cause of the patient’s HES (e.g., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy)

- Nucala for provider administration is medically necessary when all of the following criteria are met:
  - Diagnosis of HES for ≥6 months; and
  - Both of the following:
    - There is no identifiable non-hematologic secondary cause of the patient’s HES (e.g., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy)
    - HES is not FIP1L1-PDGRα kinase-positive
  and
  - Documentation required to support one of the following:
    - Physician attestation that the patient or caregiver are not competent or are physically unable to administer the Nucala product FDA labeled for self-administration; or
    - Patient has experienced severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, or hypotension) to Nucala within the past 6 months and requires administration and direct monitoring by a healthcare professional; or
    - Patient is new to therapy with Nucala and requires initial dose to be directly monitored by a healthcare professional before continued self-administration (Note: authorization will be for 1 dose); and
  - Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting both of the following:
    - Baseline (pre-mepolizumab treatment) blood eosinophil level ≥1000 cells/µL within the past 4 weeks; and
    - Patient is currently receiving a stable dose of background HES therapy (e.g., oral corticosteroid, immunosuppressor, or cytotoxic therapy)
Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) and

- Patient is not receiving Nucala in combination with any of the following:
  - Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab)]
  - Anti-IgE therapy [e.g., Xolair (omalizumab)]
  - Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Prescribed by an allergist, immunologist, hematologist, cardiologist, or pulmonologist; and
- Initial authorization will be for no more than 6 months

- Reauthorization/Continuation of Care Criteria
  Nucala, for provider administration, for the treatment of HES, authorization for continued use will be approved based on all of the following criteria:
  - Documentation of positive clinical response as demonstrated by at least one of the following:
    - Reduction in frequency of HES flares
    - Maintenance or reduction in background HES therapy requirements
    and
  - Documentation required to support one of the following:
    - Physician attestation that the patient or caregiver are not competent or are physically unable to administer the Nucala product FDA labeled for self-administration; or
    - Patient has experienced severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, or hypotension) to Nucala within the past 6 months and requires administration and direct monitoring by a healthcare professional
    and
  - Patient is not receiving Nucala in combination with any of the following:
    - Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab)]
    - Anti-IgE therapy [e.g., Xolair (omalizumab)]
    - Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
    and
  - Prescribed by an allergist, immunologist, hematologist, cardiologist, or pulmonologist; and
  - Initial authorization will be for no more than 12 months

Cinqair, Fasenra, and Nucala are unproven and not medically necessary in the following:1,2,8
- Acute bronchospasm
- Chronic obstructive pulmonary disease (COPD)
- Granulomatosis with polyangiitis (Wegener’s)
- Microscopic polyangiitis
- Organ or Life-threatening EGPA
- Other eosinophilic conditions
- Status asthmaticus

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
<th>NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0517</td>
<td>Injection, benralizumab, 1 mg</td>
<td>00310-1730-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00310-1830-30</td>
</tr>
<tr>
<td>J2182</td>
<td>Injection, mepolizumab, 1 mg</td>
<td>00173-0881-01</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00173-0892-01</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00173-0892-42</td>
</tr>
</tbody>
</table>

Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®)
UnitedHealthcare Commercial Medical Benefit Drug Policy
Effective 05/01/2021
Background

Asthma is a common chronic inflammatory disease of the airways that affects an estimated 24 million adults and children. Although the disease is well controlled with inhaled therapy in most patients, approximately 1.2-2.4 million people have severe asthma (i.e., 5-10% of the asthma population) that is associated with substantial morbidity, mortality, and economic effects. Asthma has been divided into subtypes, some of which are associated with airway inflammation with eosinophils. It is estimated that about half of individuals with severe asthma exhibit the eosinophilic phenotype with elevated eosinophil levels (a marker of inflammation) in both the blood and airways. Activated eosinophils can increase airway smooth muscle contraction and mucous secretion, which are hallmarks of asthma. Interleukin-5 (IL-5) is an important cellular signal in eosinophilic inflammation. Therapies that decrease IL-5 levels, such as Nucala (mepolizumab) and Cinqair (reslizumab), may decrease eosinophils in lung tissue. Fasenra (benralizumab) directly binds to the human IL-5 receptor on the surface of eosinophils and basophils, leading to the apoptosis of these cells through antibody-dependent cell mediated cytotoxicity.4,7,9,10

Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome) is characterized by asthma, sinusitis, pulmonary infiltrates, neuropathy, and eosinophilic vasculitis of one or more end organs. It is thought that eosinophils mediate the effects in patients with EGPA by infiltrating tissue and vasculature, causing inflammation. Systemic glucocorticoids are currently the standard of treatment for EGPA, however, some patients do not have sufficient response to therapy. Mepolizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma and EGPA has not been definitively established.1,13

Hypereosinophilic Syndrome (HES) is a disorder marked by the sustained overproduction of eosinophils associated with damage to one or more organs due to eosinophilic infiltration and mediator release. HES is rare and the true prevalence is unknown. One study that used clinician coding of eosinophilia to identify patients with HES in the Surveillance, Epidemiology, and End Results (SEER) database, concluded the estimated prevalence was between 0.36 to 6.3 per 100,000. Most patients are between 20 and 50 years of age at the time of diagnosis, although HES can develop in children. One study suggested that the frequencies of clinical HES variants (including myeloproliferative variants) were similar in children and adults. Certain variants of HES (i.e., those associated with aberrations in the gene for tyrosine kinase receptor platelet-derived growth factor receptor alpha [PDGFRA] and platelet-derived growth factor beta [PDGFRB]) occur almost exclusively in males, whereas others (lymphocytic variant HES [L-HES] and HES of unknown etiology) appear to be equally distributed between the sexes. Patients with HES usually have more than 1500 eosinophils/µL in their blood for 6 months or more, and the cause cannot be identified. The eosinophils disperse to various tissues, causing inflammation and eventually organ dysfunction. Mepolizumab binds to IL-5 inhibiting the production of eosinophils, thereby reducing inflammation.16, 17, 18

Benefit Considerations

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions.
decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy. Benefit coverage for an otherwise unproven service for the treatment of serious rare diseases may occur when certain conditions are met. See the Policy and Procedure addressing the treatment of serious rare diseases.

Clinical Evidence

Proven

**Eosinophilic Granulomatosis with Polyangiitis (EGPA)**

Mepolizumab is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).\(^1\)

In a post hoc analysis of the phase III clinical trial, Steinfeld et al, investigated the clinical benefit of mepolizumab in patients with EGPA that factors in remission, oral glucocorticoid (OGC) dose reduction, and EGPA relapses.\(^1\) The post hoc clinical benefit was defined as: remission at any time (2 definitions used), 50% or greater OGC dose reduction during weeks 48 to 52, or no EGPA relapses. The 2 remission definitions were Birmingham Vasculitis Activity Score of 0 plus OGC dose of 4 mg/d or less (remission 1/clinical benefit 1) or 7.5 mg/d or less (remission 2/clinical benefit 2). Clinical benefit was assessed in all patients and among subgroups with a baseline blood eosinophil count of less than 150 cells/\(\mu\)L, baseline OGC dosage of greater than 20 mg/d, or weight of greater than 85 kg. With mepolizumab versus placebo, 78% versus 32% of patients experienced clinical benefit 1, and 87% versus 53% of patients experienced clinical benefit 2 (both \(P < .001\)). Significantly more patients experienced clinical benefit 1 with mepolizumab versus placebo in the blood eosinophil count less than 150 cells/\(\mu\)L subgroup (72% vs 43%, \(P = .033\)) and weight greater than 85 kg subgroup (68% vs 23%, \(P = .005\)); in the OGC greater than 20 mg/d subgroup, results were not significant but favored mepolizumab (60% vs 36%, \(P = .395\)). The authors concluded that the majority of patients with EGPA experienced benefit with mepolizumab.

In a multicenter, double-blind, parallel-group, phase 3 trial, Wechsler et al, evaluated the efficacy and safety mepolizumab versus placebo for eosinophilic granulomatosis with polyangiitis (EGPA).\(^1\) Patients with relapsing or refractory EGPA were randomly assigned to receive 300 mg of mepolizumab (n=68) or placebo (n=68) subcutaneously every 4 weeks, plus standard care, for 52 weeks. Patients had to have received treatment for at least 4 weeks and were taking stable corticosteroid dosing for at least 4 weeks. The two primary end points were the accrued weeks of remission over the 52 week period, and the proportion of participants in remission at both week 36 and week 48. Secondary endpoints included: time to first relapse and average daily glucocorticoid use at weeks 48 through 52. Patients receiving mepolizumab had significantly more accrued weeks of remission than placebo (28% vs. 3% had 24 weeks of accrued remission; odds ratio, 5.91; 95% confidence interval (CI), 2.68 to 13.03; \(P<0.001\)) and a higher percentage of patients were in remission at both week 36 and week 48 (32% vs. 3%; odds ratio, 16.74; 95% CI, 3.61 to 77.56; \(P<0.001\)). Remission did not occur in 47% of the patients in the mepolizumab group versus 81% of those in the placebo group. The annualized relapse rate was 1.14 in the mepolizumab group, as compared with 2.27 in the placebo group (rate ratio, 0.50; 95% CI, 0.36 to 0.70; \(P<0.001\)). A total of 44% of the patients in the mepolizumab group, as compared with 7% of those in the placebo group, had an average daily dose of prednisolone or prednisone of 4.0 mg or less per day during weeks 48 through 52 (odds ratio, 0.20; 95% CI, 0.09 to 0.41; \(P<0.001\)). The authors concluded that in patients with EGPA, mepolizumab resulted in significantly more weeks in remission and a higher proportion of patients in remission than placebo, although only half of the patients treated with mepolizumab had protocol-defined remission.

**Severe Eosinophilic Asthma**

Benralizumab is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.\(^1\)

Mepolizumab is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.\(^1\)

Reslizumab is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.\(^2\)
**Hypereosinophilic Syndrome**

Mepolizumab is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

In a multicenter, randomized, placebo-controlled, 32-week treatment trial. Patients with non-hematologic secondary HES (e.g., drug hypersensitivity, parasitic helmint infection, HIV infection, non-hematologic malignancy) or FIP1L1-PDGFRα kinase-positive HES were excluded from the trial. Patients received 300 mg of Nucala (n=54) or placebo (n=54) subcutaneously once every 4 weeks. Patients were required to have been on a stable dose of background HES therapy (oral corticosteroids, immunosuppressive, or cytotoxic therapy) for 4 weeks prior to randomization and continue their therapy throughout the trial. Patients entering the trial had experienced at least 2 HES flares within the past 12 months and blood eosinophil count of 1,000 cells/mcL or higher during screening. The primary endpoint was percentage of patients who experienced ≥1 HES flare during the 32-week treatment period or who withdrew from the study. A HES flare was defined as a HES related clinical manifestation based on a physician-documented change in clinical signs or symptoms which resulted in need for an increase in the maintenance oral corticosteroid dose by at least 10 mg per day for 5 days or an increase in or addition of any cytotoxic or immunosuppressive HES therapy. HES flare was also defined as receipt of two or more courses of blinded active oral corticosteroid during the treatment period. The secondary endpoints included time to first flare, proportion of patients who experienced flares during Week 20 to Week 32, and number of HES flares per participant per year. Over the 32-week treatment period, the incidence of HES flare was 56% for the placebo group and 28% for the Nucala group (odds ratio, 0.28; 95% CI 0.12 to 0.64; P=0.002). The risk of first HES flare over the treatment period was 66% lower for patients treated with Nucala compared to placebo (hazard ratio: 0.34; 95% CI 0.18 to 0.72; P=0.002). From Week 20 through Week 32, significantly fewer patients experienced a HES flare or withdrew from the trial when treated with Nucala compared with placebo (17% versus 35%, respectively; P=0.02; odds ratio, 0.33; 95% CI: 0.13 to 0.85). Patients who received Nucala experienced significantly fewer HES flares during a 32-week treatment period compared with the placebo group (rate ratio, 0.35; 95% CI 0.19 to 0.63; Wilcoxon P value (unadjusted/adjusted) 0.002/0.02).

**Professional Societies**

**Global Initiative for Asthma**

The Global Initiative for Asthma (GINA, 2020) recommends that for Step 5 treatment, adults and adolescents, may be treated with benralizumab, mepolizumab, or reslizumab as follows:6

- Consider add-on anti-interleukin-5/5R treatment or anti-interleukin 5 receptor treatment for those with severe eosinophilic asthma that is uncontrolled on Step 4-5 treatment.
- Step 5: Refer for phenotypic investigation and/or add-on treatment. Patients with uncontrolled symptoms and/or exacerbations despite Step 4 treatment should be referred to a specialist with expertise in investigation and management of severe asthma.
- Add-on treatments for severe eosinophilic asthma include: anti-interleukin 5 treatment (subcutaneous mepolizumab for patients aged ≥ 12 years; intravenous reslizumab for ages ≥ 18 years), anti-interleukin 5 receptor treatment (subcutaneous benralizumab for ages ≥ 12 years) with severe asthma that is uncontrolled on Step 4-5 treatment, or anti-interleukin-4R α treatment (subcutaneous dupilumab for ages ≥ 12 years) with severe Type 2 asthma, or requiring treatment with maintenance OCS.

**Institute for Clinical and Economic Review (ICER)**

On March 14, 2016, the Institute for Clinical and Economic Review (ICER) released a clinical report entitled, “Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks.” ICER recommendations are as follows: 4

- ICER judges the current body of evidence on mepolizumab to be “comparable or better.”
- For adult patients with severe eosinophilic asthma, ICER judges there to be moderate certainty of a comparable or better net benefit for mepolizumab 100mg SC every four weeks as add-on maintenance treatment compared with standard of care including high dose ICS, LABA, and additional controller medications. There is moderate certainty because both the MENSIA trial, which demonstrated a significant reduction in asthma exacerbations, and the SIRIUS trial, which demonstrated a significant reduction in oral corticosteroids dosage, were relatively small studies of short duration. There remains uncertainty about the long-term durability of the benefits of the therapy and about the potential harms from modulation of the immune system. Ongoing post-marketing trials and extension studies evaluating mepolizumab may...
demonstrate a wide variety of outcomes, from substantial net health benefit to a comparable net benefit given the potential harms associated with the monoclonal antibody (opportunistic infection, anaphylaxis).

On November 13, 2018, ICER released a clinical report entitled, “Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks.” ICER recommendations are as follows: 5

- ICER judges the current body of evidence on omalizumab and mepolizumab to be “incremental” compared to standard of care.
- ICER judges the current body of evidence on reslizumab, benralizumab, and dupilumab to be “comparable or better” compared with standard of care.
- Comparisons between biologic therapies for asthma resulted in low certainty in the comparative clinical effectiveness of agents, and was given an I rating, or insufficient.

European Respiratory Society (ERS)/American Thoracic Society (ATS)
The European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines define severe asthma as that which requires treatment with high-dose ICSs plus a second controller (or systemic corticosteroids) to prevent progression to uncontrolled disease status or continuing uncontrolled disease status despite this therapy. 3 The guidelines recommend that, “While the anti-IL5 antibody, mepolizumab, was not beneficial in unselected adult patients with moderate asthma, when studied in severe asthma patients with persistent sputum eosinophilia, two anti-IL-5 antibodies, mepolizumab and reslizumab, have been shown to decrease exacerbations and oral corticosteroid use, as well as improve symptoms and lung function to varying degrees.”

Unproven
Nucala and Cinqair have additional uses listed in the FDA-label:1-2

- Other eosinophilic conditions
- Acute bronchospasm
- Status asthmaticus
- Chronic obstructive pulmonary disease (COPD)

Statistically robust randomized controlled trials are necessary to establish the safety and efficacy of Fasenra, Nucala and Cinqair to treat these conditions.1-2,8,10

U.S. Food and Drug Administration (FDA)
This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Cinqair (reslizumab)
Cinqair is approved by the U.S. Food and Drug Administration (FDA) for the add-on maintenance treatment of patients with severe asthma aged 18 years and older, who have an eosinophilic phenotype. Cinqair is not indicated for the treatment of other eosinophilic conditions or for acute bronchospasm or status asthmaticus. Because of the risk of anaphylaxis, healthcare providers administering Cinqair should observe patients closely for an appropriate period of time and be prepared to manage anaphylaxis that can be life-threatening.2

Fasenra (benralizumab)
Fasenra is approved by the U.S. Food and Drug Administration (FDA) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, who have an eosinophilic phenotype. Fasenra is not indicated for the treatment of other eosinophilic conditions or for acute bronchospasm or status asthmaticus.10

Nucala (mepolizumab)
Nucala is approved by the U.S. Food and Drug Administration (FDA) for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, who have an eosinophilic phenotype. Nucala is not indicated for the treatment of other eosinophilic conditions or for acute bronchospasm or status asthmaticus. Nucala is also indicated for the treatment of adult patient with eosinophilic granulomatosis with polyangiitis (EGPA) and the treatment of adult and pediatric patients aged 12
years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.¹

**Centers for Medicare and Medicaid Services (CMS)**

Medicare does not have a National Coverage Determination (NCD) for Cinryze® (C1 esterase inhibitor [human]), Berinert® [C1 Esterase Inhibitor (Human)], Ruconest® (C1 esterase inhibitor [recombinant]) or Kalbitor® (ecallantide) injection for the treatment of Hereditary Angioedema (HAE). Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) do not exist at this time.

In general, Medicare may cover outpatient (Part B) drugs that are furnished "incident to" a physician's service provided that the drugs are not usually self-administered by the patients who take them. Refer to the Medicare Benefit Policy Manual, Chapter 15, §50 - Drugs and Biologicals, (Accessed February 11, 2021)

*Preferred therapy criteria is not applicable for Medicare Advantage members.

**References**

1. Nucala® [prescribing information]. Research Triangle Park, NC; GlaxoSmithKline, LLC; September 2020.

2. Cinqair® [prescribing information]. Frazer, PA; Teva Respiratory, LLC; February 2020.


11. Fasenra® [prescribing information]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; October 2019.


Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®)


### Policy History/Revision Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>05/01/2021</td>
<td><strong>Coverage Rationale</strong></td>
</tr>
<tr>
<td></td>
<td>○ Added coverage criteria for treatment of Hypereosinophilic Syndrome (HES) using Nucala to indicate:</td>
</tr>
<tr>
<td></td>
<td>  ○ Nucala for provider administration is proven for patients who meet the following criteria:</td>
</tr>
<tr>
<td></td>
<td>    ▪ Diagnosis of HES for ≥ 6 months; and</td>
</tr>
<tr>
<td></td>
<td>    ▪ There is no identifiable non-hematologic secondary cause of the patient’s HES (e.g., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy)</td>
</tr>
<tr>
<td></td>
<td>  ○ Nucala for provider administration is medically necessary when all of the following criteria are met:</td>
</tr>
<tr>
<td></td>
<td>    ▪ Diagnosis of HES for ≥ 6 months; and</td>
</tr>
<tr>
<td></td>
<td>    ▪ Both of the following:</td>
</tr>
<tr>
<td></td>
<td>      ▪ There is no identifiable non-hematologic secondary cause of the patient’s HES (e.g., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy); and</td>
</tr>
<tr>
<td></td>
<td>      ▪ HES is not FIP1L1-PDGRα kinase-positive</td>
</tr>
<tr>
<td></td>
<td>  ▪ Documentation required to support one of the following:</td>
</tr>
<tr>
<td></td>
<td>    ▪ Physician attestation that the patient or caregiver are not competent or are physically unable to administer the Nucala product FDA labeled for self-administration; or</td>
</tr>
<tr>
<td></td>
<td>    ▪ Patient has experienced severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, or hypotension) to Nucala within the past 6 months and requires administration and direct monitoring by a healthcare professional; or</td>
</tr>
<tr>
<td></td>
<td>    ▪ Patient is new to therapy with Nucala and requires initial dose to be directly monitored by a healthcare professional before continued self-administration (Note: authorization will be for 1 dose)</td>
</tr>
<tr>
<td></td>
<td>  ▪ Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting both of the following:</td>
</tr>
<tr>
<td></td>
<td>    ▪ Baseline (pre-mepolizumab treatment) blood eosinophil level ≥1000 cells/µL within the past 4 weeks; and</td>
</tr>
<tr>
<td></td>
<td>    ▪ Patient is currently receiving a stable dose of background HES therapy (e.g., oral corticosteroid, immunosuppressor, or cytotoxic therapy)</td>
</tr>
<tr>
<td></td>
<td>  ▪ Patient is not receiving Nucala in combination with any of the following:</td>
</tr>
<tr>
<td></td>
<td>    ▪ Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab)]</td>
</tr>
<tr>
<td></td>
<td>    ▪ Anti-IgE therapy [e.g., Xolair (omalizumab)]</td>
</tr>
<tr>
<td></td>
<td>    ▪ Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]</td>
</tr>
<tr>
<td></td>
<td>  ▪ Prescribed by an allergist, immunologist, hematologist, cardiologist, or pulmonologist; and</td>
</tr>
<tr>
<td></td>
<td>  ▪ Initial authorization will be for no more than 6 months</td>
</tr>
<tr>
<td></td>
<td><strong>o Nucala for provider administration for the treatment of HES authorization for continued use will be approved based on all of the following criteria:</strong></td>
</tr>
<tr>
<td></td>
<td>  ▪ Documentation of positive clinical response as demonstrated by at least one of the following:</td>
</tr>
<tr>
<td></td>
<td>    ▪ Reduction in frequency of HES flares</td>
</tr>
</tbody>
</table>
### Summary of Changes

- Maintenance or reduction in background HES therapy requirements and
- Documentation required to support one of the following:
  - Physician attestation that the patient or caregiver are not competent or are physically unable to administer the Nucala product FDA labeled for self-administration; or
  - Patient has experienced severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, or hypotension) to Nucala within the past 6 months and requires administration and direct monitoring by a healthcare professional and
- Patient is not receiving Nucala in combination with any of the following:
  - Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab)]
  - Anti-IgE therapy [e.g., Xolair (omalizumab)]
  - Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
  - Prescribed by an allergist, immunologist, hematologist, cardiologist, or pulmonologist; and
  - Authorization will be for no more than 12 months

### Applicable Codes
- Added ICD-10 diagnosis code D72.11

### Supporting Information
- Updated Background, Clinical Evidences, FDA, and References sections to reflect the most current information
- Archived previous policy version 2021D0055J

### Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Benefit Drug Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](https://www.cms.gov/medicare-coverage-database/coding-and-coverage/determinations-rules)).

UnitedHealthcare may also use tools developed by third parties, such as the InterQual criteria, to assist us in administering health benefits. UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.